← Eichor
Condition: Hormone Receptor Positive Early Breast Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hormone Receptor Positive Early Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemothera
NA · 1 location(s) · Gencurix, Inc. · NCT04278469Tirzepatide Weight Loss for MRD+ Early Breast Cancer
Phase 2 · 1 location(s) · Baylor Research Institute · NCT06517212CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT07366112Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stag
Phase 2 · 17 location(s) · Merck Sharp & Dohme LLC · NCT06797635Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NA · 39 location(s) · Natera, Inc. · NCT07214532NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
Phase N/A · 1 location(s) · Henan Cancer Hospital · NCT06781281Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Phase 2 · 2 location(s) · Baylor Breast Care Center · NCT05020860Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for
NA · 1 location(s) · Medical College of Wisconsin · NCT06106477Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Phase 3 · 229 location(s) · Novartis Pharmaceuticals · NCT05827081Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
Phase 2 · 7 location(s) · Rutgers, The State University of New Jersey · NCT06518837A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Wo
Phase 1 · 1 location(s) · Rovi Pharmaceuticals Laboratories · NCT07401381Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer
Phase N/A · 1 location(s) · Institute of Oncology Ljubljana · NCT06650423Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer
Phase N/A · 1 location(s) · University Hospital Tuebingen · NCT05878314Ablation Compare With Surgery for Early Breast Cancer
NA · 1 location(s) · Peking University People's Hospital · NCT07484087ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06970912Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06341894Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemo
Phase 3 · 4 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07400523A Study of the TheraBionic P1 Device in Breast Cancer
NA · 8 location(s) · Barbara Ann Karmanos Cancer Institute · NCT07218432Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2 · 1 location(s) · Fudan University · NCT05582499Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Recep
Phase 2 · 9 location(s) · Jonsson Comprehensive Cancer Center · NCT04553770I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Phase 2 · 42 location(s) · QuantumLeap Healthcare Collaborative · NCT01042379the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07380646Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
Phase N/A · 1 location(s) · Institut fuer Frauengesundheit · NCT07531693A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3 · 317 location(s) · Merck Sharp & Dohme LLC · NCT06966700A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuva
Phase 3 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT06781996The Benefits of Continued Use of Ovarian Function Suppression After 5 Years
Phase N/A · 1 location(s) · Hongmei Zheng, PhD · NCT06050109A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
Phase 2 · 2 location(s) · National Taiwan University Hospital · NCT05766410Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-S
NA · 4 location(s) · Emory University · NCT06534125Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breas
Phase 3 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05760612Effects of Physical Activity in Early Stage Hormone Receptor Positive Breast Cancer Patients
Phase N/A · 1 location(s) · Centro di Riferimento Oncologico - Aviano · NCT07539038
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.